Clinical research of pingyangmycin lipiodol emulsion in hepatic arterial chemoembolization for large primary liver cancer

Objective The safety, technology achievement ratio and curative effect of pingyangmycin lipiodol emulsion (PLE) in hepatic arterial chemoembolization for large primary liver cancer were retrospectively evaluated in order to improve the life quality and survival rate of patients with large primary liver cancer.Methods Twenty cases of large primary liver cancer (laboratory group) were performed ultraselective transcatheter arterial chemoembolization (TACE) with PLE. Twenty-four patients with large primary liver cancer received TACE with mitomycin lipiodol emulsion (MLE) was set as control group. Variation of tumor size, tumor vessel and survival rate was compared between the two groups.Results Tumor minification was more striking in laboratory group than that of control group (χ2=7.51,P0.05). So was alpha fetoprotein (AFP) decrease (χ2=8.290,P0.05). The 6, 12, 24 and 36 month survival rate were 95% (19/20), 70% (14/20), 30% (6/20), 20% (4/20) respectively in laboratory group and 80% (19/24), 54% (13/24), 21% (5/24) and 13% (3/24) respectively in control group. There was statistical difference of survival rate between the two groups.Conclusion The safety and curative effect of PLE in hepatic arterial chemoembolization for large primary liver cancer are superior to those of MLE TACE.